FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286293789> ?p ?o ?g. }

• W4286293789 endingPage "1531" @default.
• W4286293789 startingPage "1531" @default.
• W4286293789 abstract "1531 Background: The goal of treatment for patients with metastatic cancer (MC) is to prolong and maintain quality of life. Patients and oncologists have questioned the current paradigm of initial dose selection for systemic therapy and want additional information about the potential trade-offs between efficacy and toxicity. However, empirical data on oncologists’ dose selection strategies and beliefs is lacking. Methods: ASCO conducted an international survey of medical oncologists who treat patients with metastatic breast or gastrointestinal cancers. Survey questions addressed experience with and attitudes towards reducing the standard dose of the first cycle of systemic therapy to minimize potential toxicity. The survey was open November 14 to December 13, 2021. Results: Among 3,099 eligible ASCO members, 367 completed the survey (response rate 12%), including 117 general oncologists (GO), 142 breast specialists (BRS), and 108 GI specialists (GIS). 77% of respondents practice in the US, 94% had experience leading a clinical trial, and 50% had been caregivers or patients themselves. Most respondents (52%) reported reducing the first dose of systemic agents at least 10% of the time in patients with MC to minimize toxicities. GIS were more likely to report reducing the first dose at least 10% of the time (72% vs. 50% of GO and 51% of BRS, p <.005). Of those who dose reduce, 89% reported discussing potential tradeoffs between efficacy and toxicity with patients. Among 10 common breast cancer drugs, capecitabine (76%) was the most likely to be dose reduced at initiation while tamoxifen (4%) was the least likely. Among 10 common GI cancer drugs, regorafenib (78%), capecitabine (71%) and sorafenib (66%) were most commonly dose reduced at initiation, while bevacizumab (7%) and panitumumab (8%) were the least likely. Overall, 65% of respondents agreed it is acceptable to lower starting doses to reduce side effects even at the potential expense of efficacy, with younger clinicians more likely to agree vs. older clinicians (72% age < 50 vs. 55% age > 50, p <.005). While the majority (53%) believe that oncologists should start with the recommended dose and lower it in response to side effects, GIS were more likely to disagree with this approach compared to BRS or GO (57% vs. 37% and 36% respectively, p <.005). In contrast, 45% of respondents believe that oncologists should start at a lower dose and consider increasing the dose for future cycles if the drug is well tolerated. There was strong support (89%) for future trials that seek to determine the minimal effective dose as opposed to the maximum tolerated dose. Conclusions: Oncologists frequently dose reduce to avoid toxicity in patients with MC but practices and attitudes regarding dose reduction vary considerably. Further research is needed to establish optimal dosing during drug development and to support oncologists and patients in selecting the starting dose in clinical practice." @default.
• W4286293789 created "2022-07-21" @default.
• W4286293789 creator A5001915853 @default.
• W4286293789 creator A5010429902 @default.
• W4286293789 creator A5022885582 @default.
• W4286293789 creator A5024199124 @default.
• W4286293789 creator A5026482426 @default.
• W4286293789 creator A5029412691 @default.
• W4286293789 creator A5037569155 @default.
• W4286293789 creator A5038911499 @default.
• W4286293789 creator A5043235685 @default.
• W4286293789 creator A5047417963 @default.
• W4286293789 creator A5053359739 @default.
• W4286293789 creator A5065695316 @default.
• W4286293789 creator A5086263845 @default.
• W4286293789 date "2022-06-01" @default.
• W4286293789 modified "2023-09-23" @default.
• W4286293789 title "Oncologists’ perspectives on individualizing dose selection for patients with metastatic cancer." @default.
• W4286293789 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.1531" @default.
• W4286293789 hasPublicationYear "2022" @default.
• W4286293789 type Work @default.
• W4286293789 citedByCount "0" @default.
• W4286293789 crossrefType "journal-article" @default.
• W4286293789 hasAuthorship W4286293789A5001915853 @default.
• W4286293789 hasAuthorship W4286293789A5010429902 @default.
• W4286293789 hasAuthorship W4286293789A5022885582 @default.
• W4286293789 hasAuthorship W4286293789A5024199124 @default.
• W4286293789 hasAuthorship W4286293789A5026482426 @default.
• W4286293789 hasAuthorship W4286293789A5029412691 @default.
• W4286293789 hasAuthorship W4286293789A5037569155 @default.
• W4286293789 hasAuthorship W4286293789A5038911499 @default.
• W4286293789 hasAuthorship W4286293789A5043235685 @default.
• W4286293789 hasAuthorship W4286293789A5047417963 @default.
• W4286293789 hasAuthorship W4286293789A5053359739 @default.
• W4286293789 hasAuthorship W4286293789A5065695316 @default.
• W4286293789 hasAuthorship W4286293789A5086263845 @default.
• W4286293789 hasConcept C121608353 @default.
• W4286293789 hasConcept C126322002 @default.
• W4286293789 hasConcept C143998085 @default.
• W4286293789 hasConcept C159110408 @default.
• W4286293789 hasConcept C185926286 @default.
• W4286293789 hasConcept C2775930923 @default.
• W4286293789 hasConcept C2777176818 @default.
• W4286293789 hasConcept C2777909004 @default.
• W4286293789 hasConcept C2779951463 @default.
• W4286293789 hasConcept C29730261 @default.
• W4286293789 hasConcept C526805850 @default.
• W4286293789 hasConcept C530470458 @default.
• W4286293789 hasConcept C535046627 @default.
• W4286293789 hasConcept C71924100 @default.
• W4286293789 hasConceptScore W4286293789C121608353 @default.
• W4286293789 hasConceptScore W4286293789C126322002 @default.
• W4286293789 hasConceptScore W4286293789C143998085 @default.
• W4286293789 hasConceptScore W4286293789C159110408 @default.
• W4286293789 hasConceptScore W4286293789C185926286 @default.
• W4286293789 hasConceptScore W4286293789C2775930923 @default.
• W4286293789 hasConceptScore W4286293789C2777176818 @default.
• W4286293789 hasConceptScore W4286293789C2777909004 @default.
• W4286293789 hasConceptScore W4286293789C2779951463 @default.
• W4286293789 hasConceptScore W4286293789C29730261 @default.
• W4286293789 hasConceptScore W4286293789C526805850 @default.
• W4286293789 hasConceptScore W4286293789C530470458 @default.
• W4286293789 hasConceptScore W4286293789C535046627 @default.
• W4286293789 hasConceptScore W4286293789C71924100 @default.
• W4286293789 hasFunder F4320308982 @default.
• W4286293789 hasIssue "16_suppl" @default.
• W4286293789 hasLocation W42862937891 @default.
• W4286293789 hasOpenAccess W4286293789 @default.
• W4286293789 hasPrimaryLocation W42862937891 @default.
• W4286293789 hasRelatedWork W2028072220 @default.
• W4286293789 hasRelatedWork W2056528636 @default.
• W4286293789 hasRelatedWork W2081876561 @default.
• W4286293789 hasRelatedWork W2111633398 @default.
• W4286293789 hasRelatedWork W2146983958 @default.
• W4286293789 hasRelatedWork W2265717204 @default.
• W4286293789 hasRelatedWork W2469700170 @default.
• W4286293789 hasRelatedWork W2944505249 @default.
• W4286293789 hasRelatedWork W3015200517 @default.
• W4286293789 hasRelatedWork W4250720993 @default.
• W4286293789 hasVolume "40" @default.
• W4286293789 isParatext "false" @default.
• W4286293789 isRetracted "false" @default.
• W4286293789 workType "article" @default.